Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 4/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782873 | 1.00 | CA1 (0.64) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL8064226 | 1.00 | CA1 (0.64) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL574092 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL7912103 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL8513608 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL13819793 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL2573740 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL11386622 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL13819794 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 | |
| SCHEMBL13538692 | 0.98 | CA1 (0.61) | CA1ACE2FDPSFAAHFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| US-9708383-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2016-11-03 | — | — | US | disclosed |
| US-20160144050-A1 | PRODRUGS ACTIVATED BY CASPASE | PHAROSGEN CO., LTD. (KR) | 2016-05-26 | — | — | US | disclosed |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2015-12-31 | — | — | US | disclosed |
| US-9056138-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20140256630-A1 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | INDI MOLECULAR, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | DYAX CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-7910088-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2011-03-22 | — | — | US | disclosed |
| WO-2011008230-A2 | RAPAMYCIN DERIVATIVES AND ETHERS OF N-PROPANOLAMINES AND USES RELATED TO INFECTION | Zirus, Inc. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010039778-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-7550433-B2 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| WO-2009061595-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2005070393-A2 | DIRECTLY COMPRESSIBLE PHARMACEUTICAL COMPOSITION OF THE RAPAMYCIN ESTER CCI-779 | WYETH (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CA1 4227/4885ACE2 2746/4885FDPS 3113/4885 |
| US-20160317623-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | CA1 1001/4885ACE2 2990/4885FDPS 2274/4885 |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CA1 1638/4885ACE2 2114/4885FDPS 2976/4885 |
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | CA1 2056/4885ACE2 3365/4885FDPS 1768/4885 |
| US-20140256630-A1 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | FLT4, FLT1, KDR | CA1 776/4885ACE2 4228/4885FDPS 3028/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | CA1 1001/4885ACE2 2990/4885FDPS 2274/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | CA1 1001/4885ACE2 2990/4885FDPS 2274/4885 |
| US-20150374843-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CA1 1638/4885ACE2 2114/4885FDPS 2976/4885 |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | EPOR, PROKR1, PROKR2 | CA1 4745/4885ACE2 1175/4885FDPS 1976/4885 |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CA1 1638/4885ACE2 2114/4885FDPS 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.